Last Updated: 17 Sep 2024
Executive Summary
Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company focused on developing therapies for liver diseases. The company's latest stock price is $3.87, with a market capitalization of $26.56 million. Galmed has a strong balance sheet with $22.24 book value per share. However, the company has been reporting losses in recent years, with an EPS of -$10.44 in the latest quarter. Analysts have a mixed view on the stock, with one analyst rating it a Buy and no Strong Buy or Strong Sell ratings.
Company Overview
Galmed Pharmaceuticals Ltd. is headquartered in Tel Aviv, Israel. The company is focused on developing therapies for the treatment of liver diseases, including non-alcoholic steatohepatitis (NASH) and cholestatic liver diseases. Galmed's lead product candidate, Aramchol, is a once-daily oral therapy for the treatment of NASH. Aramchol is currently in Phase 3 clinical trials.
Fundamental Analysis
Galmed Pharmaceuticals Ltd. has a strong balance sheet with $22.24 book value per share. The company has no debt and $13.7 million in cash and cash equivalents. However, Galmed has been reporting losses in recent years, with an EPS of -$10.44 in the latest quarter. The company's revenue is also declining, with $0 in revenue in the latest quarter.
Technical Analysis
The technical analysis of Galmed Pharmaceuticals Ltd. shows that the stock is currently trading below its 50-day and 200-day moving averages. The stock has also been making lower lows and lower highs in recent months. This indicates that the stock is in a downtrend and could continue to decline in the short term.
Short Term Outlook
The short-term outlook for Galmed Pharmaceuticals Ltd. is negative. The stock is currently trading below its moving averages and is in a downtrend. The company is also reporting losses and has no revenue. This indicates that the stock could continue to decline in the short term.
Long Term Outlook
The long-term outlook for Galmed Pharmaceuticals Ltd. is uncertain. The company's lead product candidate, Aramchol, is in Phase 3 clinical trials. If Aramchol is successful in these trials, it could be a major revenue generator for the company. However, there is no guarantee that Aramchol will be successful in clinical trials.
Analyst Recommendations
Analysts have a mixed view on Galmed Pharmaceuticals Ltd. One analyst rates the stock a Buy, while no analysts rate it a Strong Buy or Strong Sell. The average analyst target price for the stock is $12.00.
